NCT07234045

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1195E CAR-T Cells Injection in Patients With Relapsed/Refractory B-Cell Neoplasms

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1195E CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms

Detailed description

This is a single-arm, open-label, dose exploratory clinical study to evaluate the safety, efficacy, cellular Metabolic Kinetics of CT1195E CAR-T Cells in patients with relapsed/refractory B-cell Non-Hodgkin's Lymphoma (R/R B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). It is planned to enroll around 20-30 participants.

Conditions

• Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
• Relapsed/Refractory B-cell ALL

Interventions

Type	Name	Description
DRUG	CAR T cells chimeric antigenreceptor cells	CT1195E cells infusion

Timeline

• Start date: 2025-11-30
• Primary completion: 2027-12-30
• Completion: 2028-06-30
• First posted: 2025-11-18
• Last updated: 2025-11-18

Locations

1 site across 1 country: China